Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Journal of Hepatology|March 28, 2017
Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analysesTania M Welzel, Neeru Bhardwaj, Charlotte Hedskog, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 21, 2017
Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without VoxilaprevirZobair M Younossi, Maria Stepanova, Stuart Gordon, et al.
Alimentary Pharmacology & Therapeutics|June 30, 2020
Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practicesZobair M Younossi, Kathleen E Corey, Naim Alkhouri, et al.
The New England Journal of Medicine|November 30, 2007
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis CJohn G McHutchison, Geoffrey Dusheiko, Mitchell L Shiffman, et al.
The American Journal of Gastroenterology|August 30, 2019
Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of LifeZobair M Younossi, Maria Stepanova, Eric J Lawitz, et al.
Cancer|July 17, 2015
Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis BW Ray Kim, Rohit Loomba, Thomas Berg, et al.
The New England Journal of Medicine|April 12, 2014
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirinJordan J Feld, Kris V Kowdley, Eoin Coakley, et al.
Antiviral Research|June 11, 2013
Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokineticsEric Lawitz, Mark Sulkowski, Ira Jacobson, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 20, 2015
Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysisJia-Horng Kao, Donald M Jensen, Michael P Manns, et al.
Hepatology (Baltimore, Md.)|August 3, 2013
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR studyMichael W Fried, Maria Buti, Gregory J Dore, et al.
Pageof 6